FDA panel rejects Avastin for breast cancer

Reuters reported: [An FDA] committee voted 5-4 that data Genentech presented failed to establish a favorable balance of risks and benefits for Avastin in advanced breast cancer patients.

The U.S. Food and Drug Administration will consider the panel's [Dec. 5]recommendation as it decides whether to approve Avastin for breast cancer. The FDA does not have to follow committee's advice but usually does.